Is Onconetix Stock a Good Investment?
Onconetix Investment Advice | ONCO |
- Examine Onconetix's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Onconetix's leadership team and their track record. Good management can help Onconetix navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Onconetix's business and its evolving consumer preferences.
- Compare Onconetix's performance and market position to its competitors. Analyze how Onconetix is positioned in terms of product offerings, innovation, and market share.
- Check if Onconetix pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Onconetix's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Onconetix stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Onconetix is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Onconetix Stock
Researching Onconetix's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.59. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Onconetix recorded a loss per share of 161.5. The entity had not issued any dividends in recent years. The firm had 1:85 split on the 13th of June 2025.
To determine if Onconetix is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Onconetix's research are outlined below:
| Onconetix generated a negative expected return over the last 90 days | |
| Onconetix has high historical volatility and very poor performance | |
| Onconetix has a very high chance of going through financial distress in the upcoming years | |
| Onconetix currently holds 9.45 M in liabilities. Onconetix has a current ratio of 0.61, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Onconetix's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 2.52 M. Net Loss for the year was (58.69 M) with profit before overhead, payroll, taxes, and interest of 911.93 K. | |
| Onconetix currently holds about 113.36 K in cash with (10.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85. | |
| Latest headline from prnewswire.com: SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates ONCO, WAT, XAGE on Behalf of Shareholders |
Onconetix Quarterly Liabilities And Stockholders Equity |
|
Onconetix uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Onconetix. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Onconetix's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Onconetix's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Onconetix's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-15 | 2023-03-31 | -0.2 | -0.18 | 0.02 | 10 | ||
2024-05-20 | 2024-03-31 | -0.21 | -0.502 | -0.292 | 139 | ||
2023-08-14 | 2023-06-30 | -0.18 | -612.0 | -611.82 | 339900 | ||
2023-03-09 | 2022-12-31 | -0.2 | -680.0 | -679.8 | 339900 | ||
2022-11-10 | 2022-09-30 | -0.27 | -918.0 | -917.73 | 339900 | ||
2024-03-07 | 2023-12-31 | -0.21 | -3404.0048 | -3403.7948 | 1620854 |
Onconetix Target Price Consensus
Onconetix target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Onconetix's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Hold |
Most Onconetix analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Onconetix stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Onconetix, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationOnconetix Target Price Projection
Onconetix's current and average target prices are 3.44 and 9.00, respectively. The current price of Onconetix is the price at which Onconetix is currently trading. On the other hand, Onconetix's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Onconetix Target Price
Onconetix Analyst Ratings
Onconetix's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Onconetix stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Onconetix's financials, market performance, and future outlook by experienced professionals. Onconetix's historical ratings below, therefore, can serve as a valuable tool for investors.Onconetix's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.8 M.Market Cap |
|
Onconetix's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (51.82) | (49.23) | |
| Return On Capital Employed | (5.71) | (5.43) | |
| Return On Assets | (2.08) | (1.98) | |
| Return On Equity | (6.11) | (5.80) |
Determining Onconetix's profitability involves analyzing its financial statements and using various financial metrics to determine if Onconetix is a good buy. For example, gross profit margin measures Onconetix's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Onconetix's profitability and make more informed investment decisions.
Evaluate Onconetix's management efficiency
Onconetix has return on total asset (ROA) of (0.0825) % which means that it has lost $0.0825 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (11.8006) %, meaning that it created substantial loss on money invested by shareholders. Onconetix's management efficiency ratios could be used to measure how well Onconetix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of July 2025, Return On Tangible Assets is likely to grow to -49.23. In addition to that, Return On Capital Employed is likely to grow to -5.43. At this time, Onconetix's Total Assets are very stable compared to the past year. As of the 19th of July 2025, Other Current Assets is likely to grow to about 202.1 K, while Non Current Assets Total are likely to drop about 20 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 297.54 | 312.42 | |
| Tangible Book Value Per Share | (539.89) | (512.89) | |
| Enterprise Value Over EBITDA | (0.18) | (0.19) | |
| Price Book Value Ratio | 0.18 | 0.17 | |
| Enterprise Value Multiple | (0.18) | (0.19) | |
| Price Fair Value | 0.18 | 0.17 | |
| Enterprise Value | 264 M | 234.7 M |
Onconetix showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 3.509 |
Basic technical analysis of Onconetix Stock
As of the 19th of July, Onconetix holds the Risk Adjusted Performance of (0.04), coefficient of variation of (1,971), and Variance of 75.71. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Onconetix, as well as the relationship between them.Onconetix's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Onconetix insiders, such as employees or executives, is commonly permitted as long as it does not rely on Onconetix's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Onconetix insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Altos Venture Ag few days ago Disposition of 241514 shares by Altos Venture Ag of Onconetix subject to Rule 16b-3 | ||
Altos Venture Ag over three weeks ago Insider Trading | ||
Altos Venture Ag over three weeks ago Insider Trading | ||
Altos Venture Ag over three weeks ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading | ||
Altos Venture Ag over a month ago Insider Trading |
Onconetix's Outstanding Corporate Bonds
Onconetix issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Onconetix uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Onconetix bonds can be classified according to their maturity, which is the date when Onconetix has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US68233JBV52 Corp BondUS68233JBV52 | View | |
| US68233JBU79 Corp BondUS68233JBU79 | View | |
| US68233JBR41 Corp BondUS68233JBR41 | View | |
| US68233JBP84 Corp BondUS68233JBP84 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBG85 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBH68 | View | |
| US68233JBD54 Corp BondUS68233JBD54 | View | |
| ONCOR ELEC DELIVERY Corp BondUS68233JBB98 | View |
Understand Onconetix's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Onconetix's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 6.55 | |||
| Coefficient Of Variation | (1,971) | |||
| Standard Deviation | 8.7 | |||
| Variance | 75.71 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (1.67) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 47.25 | |||
| Value At Risk | (15.78) | |||
| Potential Upside | 13.77 | |||
| Skewness | (0.28) | |||
| Kurtosis | 0.8784 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 6.55 | |||
| Coefficient Of Variation | (1,971) | |||
| Standard Deviation | 8.7 | |||
| Variance | 75.71 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (1.67) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 47.25 | |||
| Value At Risk | (15.78) | |||
| Potential Upside | 13.77 | |||
| Skewness | (0.28) | |||
| Kurtosis | 0.8784 |
Consider Onconetix's intraday indicators
Onconetix intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Onconetix stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Onconetix time-series forecasting models is one of many Onconetix's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Onconetix's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Onconetix Stock media impact
There is far too much social signal, news, headlines, and media speculation about Onconetix that are available to investors today. This information is accessible both publicly - through Onconetix's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Onconetix-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Onconetix news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Onconetix relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Onconetix's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Onconetix alpha.
Onconetix Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Onconetix can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Onconetix Historical Investor Sentiment
Investor biases related to Onconetix's public news can be used to forecast risks associated with an investment in Onconetix. The trend in average sentiment can be used to explain how an investor holding Onconetix can time the market purely based on public headlines and social activities around Onconetix. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Onconetix's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Onconetix and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Onconetix news discussions. The higher the estimate score, the more favorable the investor's outlook on Onconetix.
Onconetix Corporate Management
| Theodore Yoho | Head Development | Profile | |
| MBA MA | Senior Development | Profile | |
| Andrew Skibo | Global Operations | Profile | |
| MD MBA | Chief Officer | Profile | |
| Christian Bruhlmann | Chief Officer | Profile | |
| Dr Very | Senior Development | Profile | |
| Erin Henderson | Consultant | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Onconetix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (161.50) | Revenue Per Share | Quarterly Revenue Growth (0.85) | Return On Assets | Return On Equity |
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Onconetix's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.